SG10202001065SA - Compositions and methods for treating neurodegenerative diseases - Google Patents
Compositions and methods for treating neurodegenerative diseasesInfo
- Publication number
- SG10202001065SA SG10202001065SA SG10202001065SA SG10202001065SA SG10202001065SA SG 10202001065S A SG10202001065S A SG 10202001065SA SG 10202001065S A SG10202001065S A SG 10202001065SA SG 10202001065S A SG10202001065S A SG 10202001065SA SG 10202001065S A SG10202001065S A SG 10202001065SA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- neurodegenerative diseases
- treating neurodegenerative
- treating
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461971862P | 2014-03-28 | 2014-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202001065SA true SG10202001065SA (en) | 2020-04-29 |
Family
ID=54196457
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202001065SA SG10202001065SA (en) | 2014-03-28 | 2015-03-27 | Compositions and methods for treating neurodegenerative diseases |
| SG11201608064WA SG11201608064WA (en) | 2014-03-28 | 2015-03-27 | Compositions and methods for treating neurodegenerative diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608064WA SG11201608064WA (en) | 2014-03-28 | 2015-03-27 | Compositions and methods for treating neurodegenerative diseases |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9802925B2 (zh) |
| EP (1) | EP3122743B1 (zh) |
| JP (2) | JP7255967B2 (zh) |
| KR (2) | KR20220151037A (zh) |
| CN (3) | CN116139282A (zh) |
| AU (2) | AU2015237253B2 (zh) |
| BR (1) | BR112016022575A2 (zh) |
| CA (1) | CA2944211C (zh) |
| DK (1) | DK3122743T3 (zh) |
| ES (1) | ES2939959T3 (zh) |
| FI (1) | FI3122743T3 (zh) |
| IL (1) | IL248074B (zh) |
| MX (2) | MX2021005502A (zh) |
| MY (1) | MY184878A (zh) |
| NZ (1) | NZ724718A (zh) |
| PL (1) | PL3122743T3 (zh) |
| RU (1) | RU2742773C2 (zh) |
| SG (2) | SG10202001065SA (zh) |
| SI (1) | SI3122743T1 (zh) |
| TW (1) | TWI736519B (zh) |
| WO (1) | WO2015148962A1 (zh) |
| ZA (1) | ZA201606673B (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2804001C (en) | 2010-07-01 | 2021-02-09 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
| BR112016022575A2 (pt) | 2014-03-28 | 2017-08-15 | Azevan Pharmaceuticals Inc | Composições e métodos para o tratamento de doenças neurodegenerativas |
| TWI622380B (zh) * | 2017-01-17 | 2018-05-01 | 正崴精密工業股份有限公司 | 生理訊號測量裝置及其血氧濃度演算方法 |
| CN111295373A (zh) * | 2017-09-15 | 2020-06-16 | 阿泽凡药物公司 | 用于治疗脑损伤的组合物和方法 |
| CN116685313A (zh) * | 2020-12-23 | 2023-09-01 | 细胞基因公司 | 用于治疗神经变性疾病的含有茚满基的羧酸化合物 |
| WO2023164710A1 (en) * | 2022-02-28 | 2023-08-31 | The Trustees Of Columbia University In The City Of New York | Avpr1a blockade to reduce social isolation-induced anxiety in females |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| US4314081A (en) | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| NL7503310A (nl) | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
| US4576753A (en) | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
| GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| US4341698A (en) | 1979-06-21 | 1982-07-27 | Richardson-Merrell Inc. | Enkaphalin derivatives |
| US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| JPS56125361A (en) | 1980-03-07 | 1981-10-01 | Sagami Chem Res Center | Azetidinone compound |
| JPS6033439B2 (ja) | 1980-03-07 | 1985-08-02 | 財団法人相模中央化学研究所 | ジペプチドの製造方法 |
| FR2508035A1 (fr) | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
| US4761501A (en) | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
| US4751299A (en) | 1983-11-18 | 1988-06-14 | Takeda Chemical Industries, Ltd. | Optically active β-lactams and method of their production |
| US4665171A (en) | 1985-07-17 | 1987-05-12 | Harvard University | Process and intermediates for β-lactam antibiotics |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4734498A (en) | 1986-07-10 | 1988-03-29 | Eli Lilly And Company | 3β-succinimidoazetidinones as chiral intermediates |
| US4772694A (en) | 1986-07-24 | 1988-09-20 | Eli Lilly And Company | Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates |
| US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
| JP3208139B2 (ja) | 1990-10-02 | 2001-09-10 | ワーナー−ランバート・コンパニー | アンギオテンシン▲ｉｉ▼アンタゴニスト |
| GB9204001D0 (en) | 1992-02-25 | 1992-04-08 | Jacobs Suchard Ag | Process for producing reduced fat nuts |
| US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5612336A (en) | 1992-07-13 | 1997-03-18 | Merck, Sharp & Dohme Ltd. | Heterocyclic amide derivatives as tachykinin antagonists |
| DE69329712T2 (de) | 1992-08-13 | 2001-04-12 | Warner Lambert Co | Tachykinin antagonistes |
| FR2696178B1 (fr) | 1992-09-30 | 1994-12-30 | Sanofi Elf | Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant. |
| HU224496B1 (hu) | 1993-05-06 | 2005-10-28 | Merrel Dow Pharmaceuticals Inc. | Pirrolidin-3-il-alkil-piperidin-származékok és e vegyületeket tartalmazó gyógyászati készítmények |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5759865A (en) | 1995-05-03 | 1998-06-02 | Eli Lilly And Company | Combinatorial process for synthesizing azetidinone analogs |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| ATE305781T1 (de) | 1996-02-23 | 2005-10-15 | Lilly Co Eli | Non-peptidische vasopressin via antagonisten |
| DK1000062T3 (da) | 1997-07-30 | 2004-11-22 | Wyeth Corp | Tricykliske vasopressinagonister |
| US6403632B1 (en) | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| PL193086B1 (pl) | 1997-10-27 | 2007-01-31 | Reddys Lab Ltd Dr | Nowe związki tricykliczne i związki pośrednie, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie |
| ATE319447T1 (de) | 1999-08-16 | 2006-03-15 | Revaax Pharmaceuticals Llc | Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen |
| GB0019006D0 (en) | 2000-08-04 | 2000-09-20 | Astrazeneca Ab | Novel compounds |
| EP1434763B1 (en) | 2001-10-12 | 2018-01-17 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl vasopressin v1a antagonists |
| WO2003051314A2 (en) | 2001-12-18 | 2003-06-26 | Medallion Biomedical, Llc | Antibiotic compounds |
| US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
| GB0224919D0 (en) | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
| CA2532971A1 (en) | 2003-07-14 | 2005-01-27 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| US20060281728A1 (en) | 2003-10-03 | 2006-12-14 | Guillon Christophe D | 3-Substituted beta-lactamyl vasopressin v1a antagonists |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| EP1669776A1 (de) | 2004-12-11 | 2006-06-14 | Leica Geosystems AG | Handhaltbares Vermessungsgerät und Vermessungsverfahren für ein solches Vermessungsgerät |
| FR2881744B1 (fr) | 2005-02-09 | 2007-04-27 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique |
| US9597314B2 (en) * | 2005-03-22 | 2017-03-21 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids for treating premenstrual disorders |
| US20080234252A1 (en) * | 2005-05-18 | 2008-09-25 | Pfizer Inc | Compounds Useful in Therapy |
| KR101523776B1 (ko) * | 2005-07-19 | 2015-05-28 | 아제반 파마슈티칼스, 인코퍼레이티드 | 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신길항물질 |
| WO2007109615A2 (en) * | 2006-03-21 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS |
| WO2008034032A2 (en) | 2006-09-14 | 2008-03-20 | Azevan Pharmaceuticals, Inc. | Beta-lactam cannabinoid receptor modulators |
| WO2008036759A1 (en) | 2006-09-22 | 2008-03-27 | Janssen Pharmaceutica N.V. | Spiro benzazepines as vasopressin antagonists |
| JP5450108B2 (ja) | 2007-03-23 | 2014-03-26 | アレイ バイオファーマ、インコーポレイテッド | グルコキナーゼ活性化剤としての２−アミノピリジン類似体 |
| FR2927625B1 (fr) * | 2008-02-19 | 2010-03-12 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique |
| FR2930249B1 (fr) * | 2008-04-21 | 2010-05-14 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique. |
| CA2804001C (en) | 2010-07-01 | 2021-02-09 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
| WO2014127350A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| BR112016022575A2 (pt) | 2014-03-28 | 2017-08-15 | Azevan Pharmaceuticals Inc | Composições e métodos para o tratamento de doenças neurodegenerativas |
| CN111295373A (zh) | 2017-09-15 | 2020-06-16 | 阿泽凡药物公司 | 用于治疗脑损伤的组合物和方法 |
-
2015
- 2015-03-27 BR BR112016022575A patent/BR112016022575A2/pt not_active Application Discontinuation
- 2015-03-27 SI SI201531921T patent/SI3122743T1/sl unknown
- 2015-03-27 KR KR1020227038057A patent/KR20220151037A/ko not_active Application Discontinuation
- 2015-03-27 SG SG10202001065SA patent/SG10202001065SA/en unknown
- 2015-03-27 EP EP15769990.1A patent/EP3122743B1/en active Active
- 2015-03-27 CN CN202310338451.5A patent/CN116139282A/zh active Pending
- 2015-03-27 FI FIEP15769990.1T patent/FI3122743T3/fi active
- 2015-03-27 US US15/129,190 patent/US9802925B2/en active Active
- 2015-03-27 MY MYPI2016703577A patent/MY184878A/en unknown
- 2015-03-27 NZ NZ724718A patent/NZ724718A/en unknown
- 2015-03-27 CN CN201580027324.7A patent/CN106459021B/zh active Active
- 2015-03-27 WO PCT/US2015/023060 patent/WO2015148962A1/en active Application Filing
- 2015-03-27 ES ES15769990T patent/ES2939959T3/es active Active
- 2015-03-27 CA CA2944211A patent/CA2944211C/en active Active
- 2015-03-27 JP JP2017502942A patent/JP7255967B2/ja active Active
- 2015-03-27 AU AU2015237253A patent/AU2015237253B2/en active Active
- 2015-03-27 SG SG11201608064WA patent/SG11201608064WA/en unknown
- 2015-03-27 DK DK15769990.1T patent/DK3122743T3/da active
- 2015-03-27 MX MX2021005502A patent/MX2021005502A/es unknown
- 2015-03-27 MX MX2016012645A patent/MX2016012645A/es unknown
- 2015-03-27 PL PL15769990.1T patent/PL3122743T3/pl unknown
- 2015-03-27 RU RU2016138349A patent/RU2742773C2/ru active
- 2015-03-27 KR KR1020167028877A patent/KR20160130853A/ko active Application Filing
- 2015-03-27 CN CN202310338535.9A patent/CN116327950A/zh active Pending
- 2015-03-30 TW TW104110388A patent/TWI736519B/zh active
-
2016
- 2016-09-27 ZA ZA2016/06673A patent/ZA201606673B/en unknown
- 2016-09-27 IL IL248074A patent/IL248074B/en active IP Right Grant
-
2017
- 2017-10-18 US US15/786,772 patent/US10364236B2/en active Active
-
2019
- 2019-06-10 US US16/436,350 patent/US11319306B2/en active Active
- 2019-10-23 AU AU2019253831A patent/AU2019253831B2/en active Active
-
2022
- 2022-04-29 US US17/732,631 patent/US20230123729A1/en active Pending
- 2022-05-09 JP JP2022077195A patent/JP2022116001A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1225651A1 (zh) | 異吲哚啉組合物和治療神經變性疾病的方法 | |
| HK1232141A1 (zh) | 用於治療亨廷頓病的方法和組合物 | |
| IL255421A0 (en) | Preparations and methods for the treatment of neurodegenerative disease | |
| SG11201705093UA (en) | Composition for treating il-6-related diseases | |
| IL246791A0 (en) | Compositions and methods for treating eye diseases | |
| EP2953950A4 (en) | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | |
| RS61929B1 (sr) | Postupci i sastavi za tretman raka | |
| IL247699A0 (en) | Preparations and methods for the treatment of kidney disorders | |
| EP3139928A4 (en) | Anordrin compositions and methods for treating diseases | |
| HUE054204T2 (hu) | Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez | |
| IL249098A0 (en) | Methods and preparations for the treatment of allergy and inflammatory diseases | |
| EP3110446A4 (en) | Methods and compositions for treating siglec-8 associated diseases | |
| HK1245127A1 (zh) | 治療腦疾病的方法和組合物 | |
| ZA201606199B (en) | Compositions and methods for treating diabetes and liver diseases | |
| ZA201606673B (en) | Compositions and methods for treating neurodegenerative diseases | |
| EP3164132A4 (en) | Methods and compositions for treating diseases and conditions | |
| ZA201605109B (en) | Compositions and methods for treating neutropenia | |
| HK1246206A1 (zh) | 用於治療青光眼的組合物和方法 | |
| EP3107534A4 (en) | Compositions and methods for the treatment of neurodegenerative diseases | |
| EP3364965A4 (en) | METHOD AND COMPOSITIONS FOR TREATING NEURODEEGENERATIVE DISEASES | |
| HK1244782A1 (zh) | 用於治療疾病和病癥的組合物和方法 | |
| GB201420348D0 (en) | Compounds for treating neurodegenerative diseases | |
| GB201521083D0 (en) | Compositions for treatment and methods thereof | |
| GB201419559D0 (en) | Therapeutic compositions and methods | |
| SG10201400823PA (en) | Therapeutic methods and compositions for treating diabetes |